The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial

The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial Publisher Pubmed

Hosseinjani H¹ ; Hadjibabaie M^{1, 2} ; Gholami K^{1, 2} ; Javadi M^{1, 2} ; Radfar M¹ ; Jahangardrafsanjani Z¹ ; Hosseinjani E³ ; Shabani N⁴ ; Vaezi M⁵ ; Ghavamzadeh A⁵

Source: Hematological Oncology Published:2017

Abstract

Oral mucositis (OM) as a complication of high-dose chemotherapy is frequently occurred in hematopoietic stem cell transplantation (HSCT) settings. Erythropoietin (EPO) has anti-inflammatory, antioxidant andwound-healing properties and therefore could have an important role in the prevention of OM. We conducted a double-blind, randomized, placebocontrolled trial to evaluate the EPO mouthwash effect onOMincidence and severity in 80 patients with non-Hodgkin’s lymphoma, Hodgkin disease (HD) or multiple myeloma, undergoing autologous hematopoietic stem cell transplantation. Patients received either EPO mouthwash (50IU/ml, 15ml four times a day) (n = 40) or placebo (n = 40) from the starting day of high-dose chemotherapy until day +14 after transplantation or until the day of discharge from the hospital, whichever occurred first. OM was evaluated daily for 21 days after transplantation or until resolution ofOMaccording toWorld Health Organization oral toxicity scale. The incidence of OM (grades 1–4) in the EPO mouthwash group and control group was significantly different (27.5% vs 77.5%, p<0.001). The mean ± SD of two other parameters of OM including maximum intensity OM score (0.60 ± 1.06 vs 1.67± 1.27) and average intensity OM score (0.47± 0.80 vs 1.28 ± 0.86) was significantly lower in the intervention group (p<0.001).Moreover, themean± SD duration ofOMwas also significantly shorter among the EPO mouthwash recipients (1.92± 3.42 days vs 5.42 ± 3.86 days, P<0.001). Also, the duration of neutropenic fever was significantly shorter in the intervention group (2.12 ± 2.42 days vs 3.95± 4.01days, p = 0.016). It is concluded that EPO mouthwash can reduce the incidence and duration of OM. © 2015 John Wiley & Sons, Ltd.

Related Docs

View other Related Docs

1. Factors Affecting the Incidence and Severity of Oral Mucositis Following Hematopoietic Stem Cell Transplantation, International Journal of Hematology-Oncology and Stem Cell Research (2018)

2. An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy, Current Pharmaceutical Biotechnology (2016)

3. An Investigation Into the Prevalence and Treatment of Oral Mucositis After Cancer Treatment, International Journal of Cancer Management (2019)

Experts (# of related papers)

View all Related Experts

Soheyla Manifar (5)

Kourosh Sadeghi (2)

Style	Citing Format
MLA	Hosseinjani H, et al.. "The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial." Hematological Oncology, vol. 35, no. 1, 2017, pp. 106-112.
APA	Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, Hosseinjani E, Shabani N, Vaezi M, Ghavamzadeh A (2017). The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial. Hematological Oncology, 35(1), 106-112.
Chicago	Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, Hosseinjani E, Shabani N, Vaezi M, Ghavamzadeh A. "The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial." Hematological Oncology 35, no. 1 (2017): 106-112.
Harvard	Hosseinjani H et al. (2017) 'The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial', Hematological Oncology, 35(1), pp. 106-112.
Vancouver	Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, et al.. The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial. Hematological Oncology. 2017;35(1):106-112.
BibTex	@article{ author = {Hosseinjani H and Hadjibabaie M and Gholami K and Javadi M and Radfar M and Jahangardrafsanjani Z and Hosseinjani E and Shabani N and Vaezi M and Ghavamzadeh A}, title = {The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial}, journal = {Hematological Oncology}, volume = {35}, number = {1}, pages = {106-112}, year = {2017} }
RIS	TY - JOUR AU - Hosseinjani H AU - Hadjibabaie M AU - Gholami K AU - Javadi M AU - Radfar M AU - Jahangardrafsanjani Z AU - Hosseinjani E AU - Shabani N AU - Vaezi M AU - Ghavamzadeh A TI - The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial JO - Hematological Oncology VL - 35 IS - 1 SP - 106 EP - 112 PY - 2017 ER -

Style

Citing Format

MLA

Hosseinjani H, et al.. "The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial." Hematological Oncology, vol. 35, no. 1, 2017, pp. 106-112.

APA

Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, Hosseinjani E, Shabani N, Vaezi M, Ghavamzadeh A (2017). The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial. Hematological Oncology, 35(1), 106-112.

Chicago

Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, Hosseinjani E, Shabani N, Vaezi M, Ghavamzadeh A. "The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial." Hematological Oncology 35, no. 1 (2017): 106-112.

Harvard

Hosseinjani H et al. (2017) 'The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial', Hematological Oncology, 35(1), pp. 106-112.

Vancouver

Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, Jahangardrafsanjani Z, et al.. The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial. Hematological Oncology. 2017;35(1):106-112.

BibTex

@article{ author = {Hosseinjani H and Hadjibabaie M and Gholami K and Javadi M and Radfar M and Jahangardrafsanjani Z and Hosseinjani E and Shabani N and Vaezi M and Ghavamzadeh A}, title = {The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial}, journal = {Hematological Oncology}, volume = {35}, number = {1}, pages = {106-112}, year = {2017} }

RIS

TY - JOUR
AU - Hosseinjani H
AU - Hadjibabaie M
AU - Gholami K
AU - Javadi M
AU - Radfar M
AU - Jahangardrafsanjani Z
AU - Hosseinjani E
AU - Shabani N
AU - Vaezi M
AU - Ghavamzadeh A
TI - The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial
JO - Hematological Oncology
VL - 35
IS - 1
SP - 106
EP - 112
PY - 2017
ER -

Science Communicator Platform

Authors

Abstract